Table 3.
Patient immunological data pre- and post-HSCT
| Patient | IgE (kU/L) | IVIG given | Vaccine responses; CSM/Mem B lymphocytes (25–75th centile reference range) | Antimicrobial prophylaxis post-HSCT | |||
|---|---|---|---|---|---|---|---|
| Pre-HSCT | Post-HSCT | Pre-HSCT | Post-HSCT | Pre-HSCT | Post-HSCT | ||
| 1 | 4007 | 1720 | Yes | No |
Normal tetanus, absent HiB and pneumococcus - |
Normal - |
Voriconazole; azithromycin |
| 2 | 75,000 | 2641 | Yes | No |
Normal - |
Normal CSM B 9% (9.2–18.9%) Mem B 13% (13.4–21.4%) |
Azithromycin |
| 3 | >6000 | 176 | Yes | No |
Normal - |
Normal - |
Doxycycline |
| 4 | 81,097 | 11,813 | Yes | No |
Normal CSM B 1% (3.3–9.6%) Mem B 3% (4.6–10.2%) |
Normal CSM B 1% (3.3–9.6%) Mem B 3% (4.6–10.2%) |
Azithromycin |
| 5 | 4487 | 1939 | No | No |
Normal CSM B 1% (3.3–9.6%) Mem B 3% (4.6–10.2%) |
Normal CSM B 2% (7.2–12.7%) Mem B 7% (7.4–13.9%) |
Posaconazole; nebulized amphotericin B; azithromycin |
| 6 | 143,000 | - | Yes | No |
Normal CSM B 0.4% (3.3–9.6%) |
- - |
- |
| 7 | >5000 | 1636 | Yes | No |
Normal - |
In progress Mem B cells 1.6% (3.3–9.6%) |
- |
| 8 | 1880–11,756 | 392 | Yes | Yes |
Normal tetanus and HiB, absent PPSV23 CSM B 2.6% (5.2–12.1%) |
(On Ig) CSM B 3% (5.2–12.1%) Mem B 2% (7.5–12.4%) |
Azithromycin |
Reference ranges of 25–75th centile for CSM and Mem B lymphocytes from Morbach et al. [15]
CSM class switched memory, HSCT hematopoietic stem cell transplantation